{"id":58539,"date":"2026-03-02T13:45:19","date_gmt":"2026-03-02T05:45:19","guid":{"rendered":"https:\/\/flcube.com\/?p=58539"},"modified":"2026-03-02T13:45:20","modified_gmt":"2026-03-02T05:45:20","slug":"antengenes-xpovio-secures-second-south-korea-reimbursement-selinexor-combo-approved-for-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58539","title":{"rendered":"Antengene&#8217;s XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma"},"content":{"rendered":"\n<p><strong>Antengene Corporation Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/6996:HKG\">HKG:\u202f6996<\/a>)<\/strong> announced that South Korea&#8217;s <strong>National Health Insurance Service (NHIS)<\/strong> has approved <strong>reimbursement for a new XPOVIO (selinexor) indication<\/strong>. Effective <strong>March\u202f1,\u202f2026<\/strong>, <strong>XPOVIO in combination with bortezomib and dexamethasone<\/strong> is now covered for <strong>adult patients with multiple myeloma (MM)<\/strong> who have received <strong>at least one prior line of therapy<\/strong>. This marks the <strong>second reimbursed indication<\/strong> for XPOVIO in South Korea and expands Antengene&#8217;s <strong>Asia\u2011Pacific market access<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-reimbursement-milestone\">Reimbursement Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Antengene Corporation Limited (HKG:\u202f6996)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>XPOVIO (selinexor)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>First\u2011in\u2011class oral selective XPO1 inhibitor<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>National Health Insurance Service (NHIS), South Korea<\/td><\/tr><tr><td><strong>Effective Date<\/strong><\/td><td>March\u202f1,\u202f2026<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>XPOVIO + bortezomib + dexamethasone for MM (\u2265\u202f1 prior therapy)<\/td><\/tr><tr><td><strong>Reimbursement Status<\/strong><\/td><td>Second XPOVIO indication covered in South Korea<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-xpovio-global-footprint\">XPOVIO Global Footprint<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Approvals<\/strong><\/td><td>Various indications across <strong>10 Asia\u2011Pacific countries\/regions<\/strong><\/td><\/tr><tr><td><strong>Public Reimbursement<\/strong><\/td><td><strong>5 markets<\/strong>: China mainland, Taiwan, Australia, Singapore, <strong>South Korea<\/strong> (new)<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td>World&#8217;s <strong>first\u2011in\u2011class oral selective XPO1 inhibitor<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Asia\u2011Pacific Reimbursement Expansion:<\/strong> South Korea joins <strong>China, Taiwan, Australia, and Singapore<\/strong> with public XPOVIO coverage, reinforcing Antengene&#8217;s <strong>regional commercial infrastructure<\/strong> and payer negotiation capabilities.<\/li>\n\n\n\n<li><strong>Multiple Myeloma Market Access:<\/strong> The <strong>combination reimbursement<\/strong> (selinexor + bortezomib + dexamethasone) addresses a <strong>large relapsed\/refractory MM population<\/strong> in South Korea, where bortezomib is widely used and reimbursed.<\/li>\n\n\n\n<li><strong>XPO1 Inhibitor Differentiation:<\/strong> As the <strong>first\u2011in\u2011class XPO1 inhibitor<\/strong>, XPOVIO offers a <strong>novel nuclear export mechanism<\/strong> distinct from proteasome inhibitors, immunomodulatory drugs, and anti\u2011CD38 antibodies\u2014supporting <strong>combination strategies<\/strong> and <strong>sequencing options<\/strong>.<\/li>\n\n\n\n<li><strong>Second Indication Validation:<\/strong> <strong>Two reimbursed indications in South Korea<\/strong> demonstrate <strong>clinical and economic value<\/strong> recognized by HTA (health technology assessment) bodies, supporting future expansion in additional Asia\u2011Pacific markets.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>South Korea MM Market<\/strong><\/td><td>~\u202f3,000\u20114,000 new MM cases annually; high unmet need in relapsed setting with limited novel mechanism options<\/td><\/tr><tr><td><strong>Asia\u2011Pacific Reimbursement Trend<\/strong><\/td><td>Growing acceptance of innovative oncology therapies in public health systems; Antengene&#8217;s 5\/10 market coverage sets benchmark for regional biotechs<\/td><\/tr><tr><td><strong>XPO1 Competitive Landscape<\/strong><\/td><td>No direct competitors; XPOVIO&#8217;s mechanism complements existing standards of care (daratumumab, carfilzomib, lenalidomide)<\/td><\/tr><tr><td><strong>Antengene Pipeline Synergy<\/strong><\/td><td>Reimbursement success supports ongoing development of XPOVIO combinations and next\u2011generation XPO1 inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding additional market reimbursement expansions, volume growth in South Korea, and XPOVIO combination development outcomes. Actual results may differ due to risks including competitive MM therapy launches, pricing pressure, and regulatory delays in remaining Asia\u2011Pacific markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antengene Corporation Limited (HKG:\u202f6996) announced that South Korea&#8217;s National Health Insurance Service (NHIS) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58541,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[136,16,926],"class_list":["post-58539","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-antengene","tag-cancer","tag-hkg-6996"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Antengene&#039;s XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Antengene Corporation Limited (HKG:\u202f6996) announced that South Korea&#039;s National Health Insurance Service (NHIS) has approved reimbursement for a new XPOVIO (selinexor) indication. Effective March\u202f1,\u202f2026, XPOVIO in combination with bortezomib and dexamethasone is now covered for adult patients with multiple myeloma (MM) who have received at least one prior line of therapy. This marks the second reimbursed indication for XPOVIO in South Korea and expands Antengene&#039;s Asia\u2011Pacific market access.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58539\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antengene&#039;s XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"Antengene Corporation Limited (HKG:\u202f6996) announced that South Korea&#039;s National Health Insurance Service (NHIS) has approved reimbursement for a new XPOVIO (selinexor) indication. Effective March\u202f1,\u202f2026, XPOVIO in combination with bortezomib and dexamethasone is now covered for adult patients with multiple myeloma (MM) who have received at least one prior line of therapy. This marks the second reimbursed indication for XPOVIO in South Korea and expands Antengene&#039;s Asia\u2011Pacific market access.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58539\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T05:45:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T05:45:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0205.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Antengene&#8217;s XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma\",\"datePublished\":\"2026-03-02T05:45:19+00:00\",\"dateModified\":\"2026-03-02T05:45:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539\"},\"wordCount\":417,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0205.webp\",\"keywords\":[\"Antengene\",\"Cancer\",\"HKG: 6996\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58539#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58539\",\"name\":\"Antengene's XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0205.webp\",\"datePublished\":\"2026-03-02T05:45:19+00:00\",\"dateModified\":\"2026-03-02T05:45:20+00:00\",\"description\":\"Antengene Corporation Limited (HKG:\u202f6996) announced that South Korea's National Health Insurance Service (NHIS) has approved reimbursement for a new XPOVIO (selinexor) indication. Effective March\u202f1,\u202f2026, XPOVIO in combination with bortezomib and dexamethasone is now covered for adult patients with multiple myeloma (MM) who have received at least one prior line of therapy. This marks the second reimbursed indication for XPOVIO in South Korea and expands Antengene's Asia\u2011Pacific market access.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58539\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0205.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0205.webp\",\"width\":1080,\"height\":608,\"caption\":\"Antengene's XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58539#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antengene&#8217;s XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Antengene's XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","description":"Antengene Corporation Limited (HKG:\u202f6996) announced that South Korea's National Health Insurance Service (NHIS) has approved reimbursement for a new XPOVIO (selinexor) indication. Effective March\u202f1,\u202f2026, XPOVIO in combination with bortezomib and dexamethasone is now covered for adult patients with multiple myeloma (MM) who have received at least one prior line of therapy. This marks the second reimbursed indication for XPOVIO in South Korea and expands Antengene's Asia\u2011Pacific market access.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58539","og_locale":"en_US","og_type":"article","og_title":"Antengene's XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma","og_description":"Antengene Corporation Limited (HKG:\u202f6996) announced that South Korea's National Health Insurance Service (NHIS) has approved reimbursement for a new XPOVIO (selinexor) indication. Effective March\u202f1,\u202f2026, XPOVIO in combination with bortezomib and dexamethasone is now covered for adult patients with multiple myeloma (MM) who have received at least one prior line of therapy. This marks the second reimbursed indication for XPOVIO in South Korea and expands Antengene's Asia\u2011Pacific market access.","og_url":"https:\/\/flcube.com\/?p=58539","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T05:45:19+00:00","article_modified_time":"2026-03-02T05:45:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0205.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58539#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58539"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Antengene&#8217;s XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma","datePublished":"2026-03-02T05:45:19+00:00","dateModified":"2026-03-02T05:45:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58539"},"wordCount":417,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58539#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0205.webp","keywords":["Antengene","Cancer","HKG: 6996"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58539#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58539","url":"https:\/\/flcube.com\/?p=58539","name":"Antengene's XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58539#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58539#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0205.webp","datePublished":"2026-03-02T05:45:19+00:00","dateModified":"2026-03-02T05:45:20+00:00","description":"Antengene Corporation Limited (HKG:\u202f6996) announced that South Korea's National Health Insurance Service (NHIS) has approved reimbursement for a new XPOVIO (selinexor) indication. Effective March\u202f1,\u202f2026, XPOVIO in combination with bortezomib and dexamethasone is now covered for adult patients with multiple myeloma (MM) who have received at least one prior line of therapy. This marks the second reimbursed indication for XPOVIO in South Korea and expands Antengene's Asia\u2011Pacific market access.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58539#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58539"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58539#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0205.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0205.webp","width":1080,"height":608,"caption":"Antengene's XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58539#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Antengene&#8217;s XPOVIO Secures Second South Korea Reimbursement \u2013 Selinexor Combo Approved for Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0205.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58539"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58539\/revisions"}],"predecessor-version":[{"id":58542,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58539\/revisions\/58542"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58541"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}